Home » Stocks » PGEN

Precigen, Inc. (PGEN)

Stock Price: $7.49 USD 0.01 (0.13%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $7.51 +0.02 (0.27%) Nov 27, 3:43 PM

Stock Price Chart

Key Info

Market Cap 1.34B
Revenue (ttm) 92.20M
Net Income (ttm) -298.08M
Shares Out 185.46M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $7.49
Previous Close $7.48
Change ($) 0.01
Change (%) 0.13%
Day's Open 7.44
Day's Range 7.15 - 7.97
Day's Volume 1,388,242
52-Week Range 1.26 - 7.97

More Stats

Market Cap 1.34B
Enterprise Value 1.44B
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 185.46M
Float n/a
EPS (basic) -1.88
EPS (diluted) -1.88
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 27.06M
Short Ratio 31.57
Short % of Float n/a
Beta 1.70
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 14.52
PB Ratio 19.26
Revenue 92.20M
Operating Income -150.16M
Net Income -298.08M
Free Cash Flow -101.28M
Net Cash -106.03M
Net Cash / Share -0.59
Gross Margin -71.95%
Operating Margin -162.86%
Profit Margin -323.30%
FCF Margin -109.84%
ROA -15.11%
ROE -122.87%
ROIC -71.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.00*
(20.16% upside)
Low
6.00
Current: $7.49
High
13.00
Target: 9.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue90.7215121919117471.9323.7613.778.01-
Revenue Growth-39.99%-31.11%14.95%9.98%141.35%202.74%72.5%71.9%--
Gross Profit29.3288.5015812911052.6723.7413.778.01-
Operating Income-204-403-95.91-125-147-69.96-58.02-75.16-82.43-24.55
Net Income-322-509-117-187-84.49-81.82-38.98-81.87-85.28-32.67
Shares Outstanding15413012011811199.1740.955.535.2446.00
Earnings Per Share-2.09-3.93-0.98-1.58-0.76-0.83-1.40-18.77-18.92-0.71
Dividend Per Share--0.25-1.71-----
Operating Cash Flow-136-124-104-48.9935.67-19.86-53.68-61.53-81.76-19.69
Capital Expenditures-37.20-39.32-45.03-31.36-12.12-6.20-1.05-7.47-12.92-0.19
Free Cash Flow-173-164-149-80.3423.55-26.05-54.73-69.00-94.68-19.88
Cash & Equivalents75.0522486.6624623911717710.66105-
Total Debt2482128.278.779.0912.641.650.09--
Net Cash / Debt-17311.7078.3923723010517610.57105-
Assets456716847949982576469152108-
Liabilities38433730038027716788.1366.5436.50-
Book Value71.71363534560694385367-32271.61-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Precigen, Inc.
Country United States
Employees 770
CEO Helen Sabzevari

Stock Information

Ticker Symbol PGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PGEN

Description

Precigen discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.